Plus   Neg

ADXS Continues To Slide, MDGL To Report NASH Data In Q2, Keep An Eye On RXII


The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.

1. RXi Pharmaceuticals Corp. (RXII)

Lost 14.89% to close Tuesday's (Mar.13) trading at $3.20. This is the second straight day of double-digit loss for the stock.

News: No news

Clinical Trials & Near-term Catalysts:

-- The lead compound is RXI-109, which successfully completed a phase II trial for dermal scarring last December.

RXI-109 is also being tested in a phase 1/2 study in an ophthalmology indication namely in patients with advanced, wet age-related macular degeneration and associated retinal scarring. Readouts from this trial are expected this month.

-- Also in the pipeline are Samcyprone, which is being evaluated in a phase IIa clinical trial in subjects with at least one cutaneous, plantar or periungual wart, and RXI-231, a cosmetic ingredient in a proprietary gel formulation designed to aid in the reduction of pigmentation to improve skin appearance.

The Company expects to share full read-outs from the Phase 2a clinical trial of Samcyprone for the treatment of cutaneous warts in Q1-Q2 2018 time period.

2. Aralez Pharmaceuticals Inc. (ARLZ)

Lost 13.86% to close Tuesday's trading at $1.74.

News: The Company reported financial results for the fourth quarter and year ended December 31, 2017.

Net loss in the fourth quarter of 2017 widened to $45.8 million or $0.68 per share from $31.1 million or $0.48 per share in the fourth quarter of 2016. Total revenues for the fourth quarter of 2017 were $28.0 million, an increase of 40%, compared to $20.0 million for the same period of 2016.

Looking ahead, the Company expects 2018 net revenue to be in a range of $140 million to $160 million. The net revenue in 2017 was $105.9 million.

3. Advaxis Inc. (ADXS)

Lost 11.76% to close Tuesday's trading at $1.95.

Recent news:

-- On Mar.12, 2018, the Company announced that the FDA placed a clinical hold on its phase 1/2 combination study of Axalimogene filolisbac with AstraZeneca's IMFINZI for the treatment of patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer.

The clinical hold was implemented following a patient death, involving respiratory failure, in the trial.

4. Daxor Corporation (DXR)

Lost 11.35% to close Tuesday's trading at $5.00.

News: No news

The Company manufactures and markets FDA-cleared BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit.

5. Madrigal Pharmaceuticals Inc. (MDGL)

Lost 10.88% to close Tuesday's trading at $127.34.

Recent events:

-- On February 8, 2018, the Company announced positive results from its phase II trial of MGL-3196 in patients with heterozygous familial hypercholesterolemia. Despite the positive results, the stock was down nearly 10% that day.

Near-term Catalysts:

-- The Company will be presenting 12-week results from an ongoing MGL-3196 Phase 2 clinical trial in patients with biopsy-proven non-alcoholic steatohepatitis (NASH) on April 13, 2018 during a main plenary session at the Annual Meeting of the European Association for the Study of the Liver (EASL). The 12-week results were reported on December 6, 2017, which sent the stock soaring over 118% that day.

The 36 weeks results from the phase II NASH trial of MGL-3196 are expected in the second quarter of 2018.

6. Atara Biotherapeutics Inc. (ATRA)

Lost 10.42% to close Tuesday's trading at $41.25.

News: No news

Recent event:

-- On Feb.28, 2018, the Company priced an underwritten public offering of 4.28 million shares of its common stock at $35.00 per share. The gross proceeds from this offering are expected to be $150.0 million.

Clinical Trials & Near-term Catalysts:

-- Two phase III trials for Tab-cel intended to support approval in the treatment of rituximab-refractory Epstein-Barr Virus-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) after hematopoietic cell transplant (HCT), dubbed MATCH, or solid organ transplant (SOT), dubbed ALLELE, are underway.
-- In January of 2018, the Company received FDA clearance to proceed with patient enrollment at U.S. sites for its ongoing global Phase 1 clinical study to evaluate ATA188 in patients with progressive or relapsing-remitting multiple sclerosis. The phase 1 study of ATA188 in MS patients was initiated in the fourth quarter of 2017 in Australia.
-- Initiate phase 1/2 study of Tab-cel in combination with Merck's KEYTRUDA for treatment of nasopharyngeal carcinoma in the second half of 2018.
-- Report the first results from the ATA188 Phase 1 study in patients with progressive MS in the first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT